← Back to Search

Behavioral Intervention

Educational Materials for Rheumatic Diseases (TANGO Trial)

N/A

Waitlist Available

Led By Maria I Danila, MD, MSc, MSPH

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (18+ years) with known AIRD

Individuals who have not obtained the updated COVID-19 vaccine series (self-report)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to find out if a new behavioral intervention in rheumatology clinics can help more people get the latest COVID-19 vaccine.

Who is the study for?

This trial is for adults over 18 with autoimmune rheumatic diseases (AIRD), specifically those of Black or Latinx ethnicity who haven't had the updated COVID-19 vaccine. Participants need phone access to join.

What is being tested?

The study tests a new approach using brochures and videos about COVID-19 vaccination and oral health, plus patient narratives, to see if they encourage AIRD patients in clinics to get vaccinated.

What are the potential side effects?

Since this trial focuses on educational materials rather than medications, there are no direct medical side effects. However, participants may experience changes in their perception or anxiety levels regarding vaccines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have not received the latest COVID-19 vaccine series.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Receipt of updated COVID-19 vaccination.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: "Storytelling" video including patient narratives, brochure and patient navigationExperimental Treatment3 Interventions

Participants will review video with narratives on COVID-19 vaccination in patients with AIRD, receive brochure on the same topic; and interact with patient navigators.

Group II: Attention Control: "Oral Health" video and "Oral Health" brochureActive Control2 Interventions

Participants will review video on the importance of oral health in patients with AIRD and receive brochure on the same topic.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Patient Navigation

2017

Completed Phase 2

~38910

0 / 2Eligibility criteria met